Contribution of postprandial versus interprandial blood glucose to HbA1c in type 1 diabetes on physiologic intensive therapy with lispro insulin at mealtime

What Was Tested

Researchers studied Insulin Lispro in this randomized controlled trial publication.

Who Took Part

According to the abstract, 24 patients were involved.

The age groups tagged for this paper are adults, both men and women.

A total of 24 type 1 diabetic patients on long-term intensive therapy with premeal human regular insulin (Hum-R) and bedtime NPH were randomly assigned to a continuation of Hum-R (group 1, n = 8), lispro (group 2, n = 8), or lispro + NPH (in variable proportions) administered at mealtime (group 3, n = 8) for 3 months, NPH administered at bedtime was continued in all three groups.

How the Study Was Run

In design terms this was a randomized study.

The patients were allocated by chance, so the Insulin Lispro group and the comparison group should start out alike.

The methods mention a period of 3 months.

Data from home blood glucose monitoring were collected, and a 24-h plasma glucose and insulin profile was obtained during a 2-day hospital visit to calculate areas under the postprandial glucose curve (3.5 h after breakfast, 3.5 h after lunch, and 3.0 h after dinner for a total of 10.0 h) and the postabsorptive blood glucose curve (the remaining 14.0 h out of 24.0 h) (AUC).

What Was Measured

The subject headings attached to it are Blood Glucose, Circadian Rhythm, Diabetes Mellitus, Type 1, Eating, Glycated Hemoglobin, Hypoglycemic Agents and Insulin.

What This Means in Plain Language

The paper is a randomized study of Insulin Lispro in 24 patients over 3 months.

With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.

Its findings take up roughly 8 sentences of the abstract and are left out here on purpose; the source paper is the place to read them.

The publication is from 1999 (Diabetes care), a journal based in United States.

More context: the Insulin Lispro compound page, all human trials.